Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 1996

Primary Completion Date

August 31, 2011

Study Completion Date

July 31, 2014

Conditions
Epstein-Barr Virus-Related Hodgkin LymphomaEpstein-Barr Virus-Related Non-Hodgkin LymphomaEBV Positive Plasma Cell Neoplasm
Interventions
BIOLOGICAL

Injection of EBV Specific CTLs

"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x 10\^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00058617 - Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | Biotech Hunter | Biotech Hunter